BCRX Stock Chart & Stats
$160.01
$0.00(0.00%)
At close: 4:00 PM EDT
$160.01
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$118.00 - $195.00
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
$35.21B
Enterprise Value$3.14K
Total Cash (Recent Filing)$352.57M
Total Debt (Recent Filing)$409.86M
Price to Earnings (P/E)―
Beta-0.20
Next Earnings
Nov 04, 2026EPS Estimate
1.6Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.44
Shares Outstanding255,535,110
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)-13.74
Price to Sales (P/S)1.87
P/FCF Ratio5.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$343.69Price Target Upside114.79% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-39.02
Revenue Forecast (FY)$11.90B
Bulls Say, Bears Say
Bulls Say
Revenue ScalingRevenue scaling from $157M in 2021 to $875M in 2025 and $941M TTM shows substantial commercial expansion. Continued ORLADEYO growth and raised total-revenue guidance indicate the company is converting product adoption into a larger operating base over the next several quarters.
Cash GenerationStrong recent operating and free cash flow provides BioCryst with internally generated funding for commercial execution, clinical development, and obligations. Positive TTM cash generation despite a reported net loss demonstrates meaningful cash conversion, although earlier periods were less consistent.
Pediatric Market ExpansionJapan’s pediatric approval expands ORLADEYO’s addressable patient population and supports broader use of its once-daily oral formulation. Regulatory access for younger HAE patients can strengthen product durability, improve geographic reach, and create additional commercial runway.
Bears Say
Strained Balance SheetPersistently negative equity and meaningful debt leave BioCryst with a constrained capital structure and limited cushion if operating conditions weaken. This can reduce financial flexibility for pipeline investment, increase leverage-related pressure, and make execution more dependent on continued cash generation.
Profitability VolatilityThe swing from positive 2025 earnings to a large TTM loss shows that profitability is not yet stable. Sharp gross-margin compression could weaken the earnings contribution of ORLADEYO and limit the company’s ability to translate revenue growth into durable operating profit.
Reduced Internal R&D CapacityEnding internal discovery and closing the Birmingham site reduces BioCryst’s in-house early-stage research capability. Although the shift is intended to lower costs and emphasize external innovation, it may narrow internal control over future programs and create execution or capability-transition risks.
BioCryst News
BCRX FAQ
What was Biocryst Pharmaceuticals’s price range in the past 12 months?
Biocryst Pharmaceuticals lowest stock price was $118.00 and its highest was $195.00 in the past 12 months.
What is Biocryst Pharmaceuticals’s market cap?
Biocryst Pharmaceuticals’s market cap is $35.21B.
When is Biocryst Pharmaceuticals’s upcoming earnings report date?
Biocryst Pharmaceuticals’s upcoming earnings report date is Nov 04, 2026 which is in 52 days.
How were Biocryst Pharmaceuticals’s earnings last quarter?
Biocryst Pharmaceuticals released its earnings results on Aug 05, 2026. The company reported $5.093 earnings per share for the quarter, beating the consensus estimate of $2.614 by $2.478.
Is Biocryst Pharmaceuticals overvalued?
According to Wall Street analysts Biocryst Pharmaceuticals’s price is currently Undervalued.
Does Biocryst Pharmaceuticals pay dividends?
Biocryst Pharmaceuticals does not currently pay dividends.
What is Biocryst Pharmaceuticals’s EPS estimate?
Biocryst Pharmaceuticals’s EPS estimate is 1.6.
How many shares outstanding does Biocryst Pharmaceuticals have?
Biocryst Pharmaceuticals has 255,535,110 shares outstanding.
What happened to Biocryst Pharmaceuticals’s price movement after its last earnings report?
Biocryst Pharmaceuticals reported an EPS of $5.093 in its last earnings report, beating expectations of $2.614. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Biocryst Pharmaceuticals?
Currently, no hedge funds are holding shares in MX:BCRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
BioCryst Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$343.69 (114.79% Upside)
$343.69 (114.79% Upside)
Blogger Sentiment
Bullish
MX:BCRX Sentiment 91%
Sector Average 62%
Sector Average 62%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
0.61%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
22.02%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Biocryst Pharmaceuticals
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on discovering and developing novel, orally administered, small-molecule therapeutics. The company currently markets two key products: Peramivir injection: An intravenous neuraminidase inhibitor, sold under the brand names RAPIVAB, RAPIACTA, and PERAMIFLU, used for the treatment of acute uncomplicated influenza. ORLADEYO: An oral serine protease inhibitor designed to manage hereditary angioedema. BioCryst's development pipeline includes several promising candidates: BCX9930: An oral factor D inhibitor in Phase II clinical trials for complement-mediated diseases. BCX9250: An oral activin receptor-like kinase-2 inhibitor undergoing Phase I clinical evaluation for fibrodysplasia ossificans progressiva. Galidesivir: An RNA dependent-RNA polymerase inhibitor, also in Phase I, aimed at treating a range of RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company engages in strategic collaborations and in-license agreements with numerous partners. These include pharmaceutical entities like Torii Pharmaceutical Co., Ltd., Seqirus UK Limited, Shionogi & Co., Ltd., Green Cross Corporation, and Mundipharma International Holdings Limited. Their alliances also extend to governmental and academic organizations such as the National Institute of Allergy and Infectious Diseases, the Biomedical Advanced Research and Development Authority, the U.S. Department of Health and Human Services, The University of Alabama at Birmingham, Albert Einstein College of Medicine of Yeshiva University, and Industrial Research, Ltd. Established in 1986, BioCryst Pharmaceuticals, Inc. is headquartered in Durham, North Carolina.
BCRX Company Deck
BCRX Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a predominantly positive operational and financial picture: strong comparable revenue growth (+45% total; ORLADEYO +10% YoY), solid cash balance (~$350M+) and non-GAAP profitability ($113.2M), successful enrollment milestones (navenibart pivotal study completed ahead of schedule), and an initiated pediatric launch with encouraging early demand (47 prescriptions). Management also reinforced financial discipline, tightened operating cost guidance, and secured a €55.7M upfront license payment. Offsetting items include a prior manufacturing delay for pediatric pellets (now shipping), a strategic wind-down of internal discovery and Birmingham facility closure that reduces in-house R&D capacity, continued competition from new injectables, and timing uncertainty for several material clinical data readouts (navenibart top line in Q3 2027; BCX17725 POC by end-2026). On balance, the positive financial and commercial momentum and clear cost discipline outweigh the challenges and transition risks.View all MX:BCRX earnings summariesBCRX Stock 12 Month Forecast
Average Price Target
$343.69
▲(114.79% Upside)